Introduction {#s1}
============

Sensory processing deficits are commonly observed in schizophrenia (SZ) and are thought to play a role in a variety of its symptoms, including perceptual distortions ([@CIT0029]) and impaired language processing ([@CIT0015]; [@CIT0038]). These deficits have been associated with reduced gray matter volume in the superior temporal gyrus ([@CIT0019]) and a reduction in dendritic spines in the auditory cortex ([@CIT0037]). Although the auditory cortex may be part of the neural substrates contributing to perceptual deficits in SZ patients, the underlying neurobiological bases are not fully understood. Several studies have used auditory steady-state responses (ASSRs) of the electroencephalogram (EEG) to probe neural network function in SZ. ASSR measures the intrinsic ability of auditory neuronal ensembles to entrain to rhythmically presented stimuli and can be assessed using EEG in humans and intracranial recordings in animals ([@CIT0003]). Human studies have consistently shown a 40-Hz deficit in ASSR, both in phase locking and evoked power, in patients with SZ ([@CIT0019]; [@CIT0004]; [@CIT0021]; [@CIT0003]; [@CIT0035]) and in family members with increased risk for SZ ([@CIT0013]), while other frequencies appeared relatively intact. As animal models could allow further exploration of mechanisms underlying ASSR deficits, we tested ASSR in rats treated with a noncompeting *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) or a GABA-A antagonist.

The NMDA receptor (NMDAR) antagonist ketamine induces a transient state in healthy human subjects that resembles some aspects of SZ ([@CIT0023]; [@CIT0017]; [@CIT0024]) and is widely used to study underlying mechanisms of the disorder in both human and animal studies. NMDAR antagonists are hypothesized to produce psychotomimetic effects by altering excitation-inhibition balance in cortical circuits, yielding alterations in oscillatory activity ([@CIT0002]; [@CIT0012]; [@CIT0028]; [@CIT0010]; [@CIT0014]). Cortical GABAergic interneurons strongly regulate network oscillations, particularly in the gamma band ([@CIT0005]; [@CIT0033]), and dysfunction in these cells is a hypothesized mechanism of SZ ([@CIT0001]; [@CIT0011]). Thus, alterations in cortical GABAergic neurotransmission may underlie abnormal oscillations in SZ patients and could be involved in the effects of NMDAR antagonists.

Here, we examined the effects of NMDA or GABA-A receptor blockade on ASSR in awake behaving rodents. Specifically, we recorded ASSR at 4 different stimulation frequencies from the A1 cortex and hippocampus using chronically implanted local field electrodes ([Figure 1](#F1){ref-type="fig"}) while simultaneously recording from a skull EEG electrode, which approximates human scalp EEG recordings (Sullivan et al., 2014). To test whether pharmacological alterations of excitatory or inhibitory neurotransmission mimic ASSR abnormalities in SZ, we assessed changes in ASSR by acute and chronic administration of MK-801, an NMDAR antagonist known to produce oscillatory changes in rodents ([@CIT0028]), and the GABA-A receptor antagonist picrotoxin (PTX).

![Electrode placement diagram. Placement of field electrodes in primary auditory (A1) cortex and hippocampal (HP). Each star represents the placement of electrode array tips as verified by histology. Data from animals with improper placement were excluded from the analysis.](ijnppy_pyu118_f0001){#F1}

Methods and Materials {#s2}
=====================

Animals and Surgery {#s3}
-------------------

All procedures were conducted according to the USPHS *Guide for the Care and Use of Laboratory Animals* and were approved by the University of Maryland School of Medicine Institutional Animal Care and Use Committee. Adult male Sprague-Dawley rats (300g upon arrival) were purchased from Charles River Laboratories (Wilmington, MA). Rats (n=18) were group-housed (3 per cage) upon arrival in a room maintained at 23°C with a 12-hour-light/-dark cycle (lights on at 7:00 [pm]{.smallcaps}) with ad libitum access to food and water. Rats were allowed 2 weeks of acclimation to the animal facility before electrode implantation. Prior to implantation of custom-made electrode arrays (Innovative Neurophysiology, Durham, NC) consisting of skull EEG electrodes and microwires for deep recordings (35 µm in diameter), rats (400--450g) were anesthetized with isoflurane (5% in oxygen for induction and 2--3% for maintenance) and placed into a stereotaxic frame using nonpuncturing ear bars. Skull EEG electrodes consisted of 2-mm-diameter Ag/AgCl disks that were cemented onto the skull surface at bregma, mimicking the human vertex EEG site where the most robust ASSR is typically recorded ([@CIT0019]). Depth electrodes were implanted in the primary auditory (A1) cortex (5.2mm caudal from bregma, 6.5mm lateral to midline, 2.2mm ventral to dura) and hippocampal (HP) CA1 region (5.2mm caudal from bregma, 5.5mm lateral, 3.8mm from dura). Arrays were secured to the skull with dental cement. Carprofen (5mg/kg i.p.) was given once daily for 72 hours postsurgery along with topical antibiotic ointment. All animals were allowed 3 weeks recovery before the recordings. At the end of the study, rats were anesthetized with chloral hydrate and transcardially perfused with 0.9% saline followed by 4% paraformaldehyde. Brains were removed and sectioned at 50 μm on a freezing microtome. Electrode tracts were identified as small lesions in the tissue using a rat brain atlas ([@CIT0027]). Only animals with appropriate electrode placement in the A1 cortex and hippocampus were used for analyses.

Recordings in Behaving Rats {#s4}
---------------------------

Recording sessions were conducted in clear 12" x 12" plexiglass boxes (Med Associates, St. Albans, VT) housed within a sound-attenuated chamber. Rats were given 3 sessions of 30 minutes each to habituate to the recording box and to being plugged in and tethered to the commutator (Plexon, Dallas, TX). Electrophysiological signals were acquired at a 1-kHz sampling rate using a 32-channel Omniplex system (Plexon). Tones were driven by an RZ6 system (Tucker Davis Technologies, Alachua, FL) and delivered via speakers mounted in the recording chambers. After 10 minutes of habituation, rats were presented with trains of 15 clicks (1 millisecond, 80 dB clicks) at 10, 20,40, and 80 Hz. Then 150 click trains were presented at each of the 4 frequencies with a 2.5-second interstimulus interval as done in humans, with the exceptions of including a higher frequency at 80 Hz, more click trains per frequency, and longer interstimulus interval ([@CIT0019]; [@CIT0013]). The duration of auditory click presentation for each stimulation frequency is as follows: 1500 milliseconds for 10-Hz stimulation, 750 milliseconds for 20-Hz stimulation, 375 milliseconds for 40-Hz stimulation, and 187 milliseconds for 80-Hz stimulation.

Acute and Chronic Drug Treatment {#s5}
--------------------------------

After 3 baseline recording sessions on consecutive days with no drug or vehicle injection, all rats were recorded under acute (+)-MK-801 hydrogen maleate (0.1mg/kg, i.p.; Sigma, St. Louis, MO) or PTX (0.5mg/kg, i.p.; Sigma). For NMDAR antagonism, MK-801 was chosen as opposed to ketamine for this study because of its substantially longer duration of action ([@CIT0028]; [@CIT0010]) and increased specificity for NMDARs ([@CIT0026]). Rats were given i.p. injections and placed in the recording chamber to habituate for 15 minutes prior to recording. After the acute recording day, each animal received daily injections in their home cage for 21 more days, followed by a recording session one day after the last injection. This study was conducted using a counterbalanced crossover design. Animals were randomly assigned into 1 of 2 groups: MK-801-PTX or PTX-MK-801. All rats had a 3-week washout period between the different drug treatments during which they remained in their home cage. Following this washout period, the group that previously received acute and chronic MK-801 was switched to acute and chronic PTX and vice versa.

Signal Processing {#s6}
-----------------

We used Neuroscan v5.4 (Compumedics, El Paso, TX) to analyze sound-evoked oscillations. EEG signals were filtered at 1 to 180 Hz and sorted into epochs poststimulus. An automated artifact rejection using an amplitude filter at ±300 µV was used for all data to reject contaminated trials. The mean number of trials accepted was 134±18. Single trial data was filtered at 1 to 180 Hz and cut into epochs corresponding to the stimulation duration (1200 milliseconds for 10 Hz, 800 milliseconds for 20 Hz, 400 milliseconds for 40 Hz, 200 milliseconds for 80 Hz). The primary variable used to assess ASSR was intertrial coherence (ITC), which measures the trial-to-trial phase synchronization for each stimulation frequency across its stimulation duration on a single trial. ITC was calculated using a Matlab script implemented in EEGLab toolbox. The ITC was averaged across the accepted single trials. Oscillatory power during the stimulation period was also calculated using a fast Fourier transform (Neuroexplorer, Plexon). These steps, including software, closely followed what we use to process human ASSR data ([@CIT0013]).

Statistical Methods {#s7}
-------------------

The MK-801/PTX and PTX/MK-801 groups were combined in all statistical analyses. SPSS and Graphpad programs were used for statistical analyses. A repeated-measures ANOVA with stimulation frequency (10, 20, 40, 80 Hz), drug (MK-801, PTX), and session (baseline, acute, chronic) all as within-subjects factors was used to test for frequency x drug, frequency x session, or 3-way interactions. A significant frequency x drug interaction was followed by posthoc Bonferroni tests at each of the 4 stimulation frequencies. These analyses were conducted first using the A1 cortex site, and if a significant effect was identified, the analysis was also applied to the hippocampus and skull EEG recordings. ITC and power were calculated separately.

Results {#s8}
=======

Local field potential ITC during ASSR in A1 {#s9}
-------------------------------------------

We investigated ITC during ASSR at 4 stimulation frequencies (10, 20, 40, and 80 Hz; [Figure 2](#F2){ref-type="fig"}) across 3 recording sessions (baseline, acute, and chronic treatment) with both MK-801 and PTX. A repeated-measures ANOVA revealed a stimulation frequency x drug interaction (F~(3,30)~=4.540, *P*=.010) and a significant main effect of session (F~(2,20)~=9.843, *P*=.001). When we analyzed individual stimulation frequencies, there was a significant drug x session effect at 20 Hz (F~(2,20)~=4.513, *P*=.024) and 40 Hz stimulation (F~(2,20)~=3.816, *P*=.039) but not at 10 Hz (*P*=.817) and 80 Hz (*P*=.180). At 20 Hz stimulation there was a significant main effect of session when comparing baseline, acute, and chronic MK-801 (F~(2,20)~=7.528, *P*=.004), with posthoc tests showing that ITC after acute MK-801 was significantly greater than at baseline (t~(10)~=3.427, *P*=.007; [Figure 3](#F3){ref-type="fig"}). However, chronic MK-801 was not significantly different from baseline (t~(10)~=0.137, *P*=.893; [Figure 3](#F3){ref-type="fig"}). Similarly, at 40 Hz stimulation, we found a significant main effect of session (F~(2,20)~=3.542, *P*=.049). Posthoc tests showed that ITC was significantly elevated after acute MK-801 (t~(10)~=2.653, *P*=.024) but not chronic MK-801 (t~(10)~=1.237, *P*=.244) compared with baseline. Repeating the above analysis for PTX, we found no significant effect of session at 20 Hz (F~(2,20)~=2.149, *P*=.143) or 40 Hz stimulation (F~(2,20)~=2.046, *P*=.155). The order of drug administration did not affect these results, as we found no significant difference after acute MK-801 between the group that received MK-801 first compared with the group that received MK-801 second at 20 Hz ASSR (t~(9)~=1.234, *P*=.248) and at 40 Hz ASSR (t~(9)~=0.581, *P*=.576). Additionally, chronic vehicle administration did not significantly affect ITC as evidenced by a lack of significant effect comparing baseline and chronic vehicle recording sessions (F~(1,5)~=0.618, *P*=.476) and no session by frequency interaction (F~(3,15)~=0.563, *P*=.648). Overall, the data indicate that acute MK-801 augments ITC in a frequency-dependent manner, exhibiting effects at 20- and 40-Hz stimulation frequencies. Chronic MK-801, or acute and chronic PTX, did not have significant effects on auditory cortex ASSR compared with baseline at the chosen dose and duration.

![Auditory steady-state response (ASSR) recorded from the primary auditory (A1) cortex. (A) Representative example of average waveforms evoked with 10-Hz stimuli (top trace). The ASSR waveform was averaged across 150 trials. Tick marks above the trace represent the presentation of auditory clicks. Bottom trace: Intertrial coherence (ITC), quantified by computing the area under the curve for the duration of the auditory stimulation. (B) Example of an average waveform evoked and ITC obtained with 20-Hz stimulation. (C) Example of average waveform and ITC evoked with 40-Hz stimulation. (D) Example of average waveform and ITC evoked with 80-Hz stimulation.](ijnppy_pyu118_f0002){#F2}

![Effect of acute and chronic MK-801 and picrotoxin (PTX) on primary auditory (A1) cortex intertrial coherence (ITC) during auditory steady-state response (ASSR). (A) Timeline showing MK-801 and PTX treatment. All animals received both drugs in a counter-balanced design with a washout period of 21 days between each treatment. (B) Mean intertrial coherence (ITC) values at 10-, 20-, 40-, and 80-Hz stimulation frequencies from 11 rats at baseline, after acute MK-801 (0.1mg/kg i.p.), and after 21-day (chronic) MK-801 treatment (0.1mg/kg i.p.). Baseline data are average values of the 3 baseline sessions for each animal, while acute and chronic data are from single sessions. ITC at 20- and 40-Hz stimulation frequencies was elevated after acute, but not chronic, MK-801. There was no significant effect of MK-801 at 10 or 80 Hz. (C) Mean ITC values at 10-, 20-, 40-, and 80-Hz stimulation frequencies from 11 rats at baseline, after acute PTX (0.5mg/kg i.p.), and after 21-day chronic PTX (0.5mg/kg i.p.). Baseline data shown are average values of the 3 baseline sessions for each animal, while acute and chronic data are from single sessions. There was no significant effect of PTX at any stimulation frequency tested. All data are plotted as mean ± SEM in this and subsequent figures. \**P*\<.05.](ijnppy_pyu118_f0003){#F3}

Oscillatory Power During ASSR in A1 {#s10}
-----------------------------------

To test whether the significant effect of acute MK-801 on ITC at 20 and 40 Hz was related to changes in oscillatory power, we examined A1 local field potential (LFP) power during auditory stimulation. Acute MK-801 did not significantly change power at 20 Hz (t~(10)~=0.2923, *P*= .776) and 40 Hz (t~(10)~=1.772, *P*=.107) compared with pre-drug values. Acute PTX also failed to affect power at 20 Hz (t~(10)~=0.619, *P*=.550) and 40 Hz (t~(10)~=1.727, *P*=.115) compared with pre-drug power. Thus, acute MK-801 augmented inter-trial synchronization in the absence of significant alterations in oscillatory power.

ITC During ASSR across Recording Sites {#s11}
--------------------------------------

To assess the location specificity of ASSR and examine the relationship between local A1 responses and skull EEG signals, we analyzed the ITC from HP and skull EEG in response to acute MK-801. The magnitude of HP and EEG ITC was much lower than that of A1 cortex at baseline and after acute MK-801 ([Figure 4](#F4){ref-type="fig"}). A repeated-measures ANOVA revealed a main effect of location at 20 Hz (F~(2,20)~=114.24, *P* \<.001) and 40 Hz (F~(2,20)~=43.73, *P*\<.001), with posthoc tests showing that A1 ITC was significantly higher in A1 than in HP and EEG (all *P*\<.001). In spite of the low coherence magnitude, the effects of acute MK-801 in the HP and EEG were similar to that observed in the A1 cortex. In the HP, acute MK-801 produced a significant increase in ITC at 40-Hz stimulation (t~(10)~=3.980, *P*=.003) but not at 20 Hz (*P*=.139). In the skull EEG, there was an insignificant decrease in ITC at 40 Hz (t~(10)~=2.108, *P*=.061) and a nominally significant increase in ITC at 20-Hz stimulation (t~(10)~=2.237, *P* =.049). Overall, the low coherence values in the HP and EEG combined with the somewhat inconsistent effects of acute MK-801 in these electrodes suggest that the A1 cortex is predominantly responsible for generating the ASSR. Furthermore, the fact that the skull EEG response is not very robust suggests that using recording A1 cortex field potentials may be the better method for studying ASSR mechanisms in rodents.

![Comparison of intertrial coherence (ITC) recorded from primary auditory (A1) cortex, hippocampus (HP), and skull EEG. (A) Mean ITC values at 20-Hz stimulation frequencies recorded from A1 cortex, HP, and skull (vertex) EEG. (B) ITC values at 40 Hz auditory steady-state response (ASSR) in the same 3 locations. There was a main effect of recording location at both 20 Hz (*P*\<.001) and 40 Hz (*P*\<.001), indicating that ITC magnitude recorded from the A1 cortex was significantly larger than the HP and vertex EEG. Acute MK-801 enhanced ITC at 40-Hz stimulation but not 20 Hz in the HP, while the vertex EEG showed increased ITC at 20 Hz but not 40 Hz. \**P*\<.05, \*\**P*\<.01.](ijnppy_pyu118_f0004){#F4}

Discussion {#s12}
==========

In this study, we demonstrated that in awake behaving rodents, acute MK-801 enhanced ASSR in beta and gamma frequencies, showing significant elevations in ITC at both 20 and 40 Hz ASSR, but not at 10 and 80 Hz ASSR. Acute PTX, at the chosen dose, did not affect ASSR at any frequency, suggesting that ASSR may be more sensitive to NMDAR than GABAergic disruption. We also showed that the MK-801-induced increase in ITC was not associated with significant changes in A1 cortex oscillatory power at the frequencies explored, indicating that synchrony was affected somewhat independently of power. Furthermore, MK-801 increased ITC, with the largest effect in the A1 cortex and weaker effects in the HP and skull EEG, suggesting that this signal was likely generated in the A1 cortex.

ASSR measures the ability of neural oscillations to entrain to auditory stimuli delivered at specific frequencies. ASSR has been shown to be disrupted in chronic SZ ([@CIT0019]; [@CIT0021]; [@CIT0003]) as well as in first-episode patients ([@CIT0034]), suggesting that it may be a useful biomarker of the disorder. A large body of work has implicated reduced activity in cortical glutamatergic ([@CIT0007]) and GABAergic ([@CIT0001]; [@CIT0011]) systems in the pathophysiology of SZ. Previous studies have measured the effect of acute NMDAR-antagonism on ASSR in anesthetized animals ([@CIT0032]) or acute GABAergic manipulations in freely moving rodents ([@CIT0039], [@CIT0040]). Building on these studies, we compared NMDAR vs GABA-A channel blockers, and their acute vs chronic effects, on ASSR in awake behaving rats. We obtained ASSR at 10-, 20-, 40-, and 80-Hz stimulation frequencies in unrestrained, awake rats. However, only 20 and 40 Hz ASSR were affected by acute MK-801. This frequency-specific effect of MK-801 is consistent with previous studies showing that NMDAR-antagonists primarily affect oscillations in the 30- to 80-Hz gamma band ([@CIT0028]; [@CIT0010]; [@CIT0014]). A recent study in anesthetized rats also tested ASSR under acute MK-801 at 10, 20, 40, and 80 Hz and similarly found that only 20- and 40-Hz phase locking was disrupted. However, in contrast to our observation of increased phase locking, [@CIT0032] found a reduction in phase locking with MK-801 at 20 and 40 Hz. The discrepancy between the 2 findings is likely due to the fact that we recorded ASSR in awake rats, while the previous study used anesthetized rats. Indeed, ASSR has been extensively shown to be affected by consciousness and is used as a metric for consciousness during surgery. In humans, ASSR at 40 Hz was shown to be drastically reduced to 15% of preanesthesia levels by isoflurane ([@CIT0029]). Additionally, ASSR has been shown to be diminished during sleep ([@CIT0022]; [@CIT0006]), indicating that a reduction in ASSR may not be primarily due to the pharmacological action of anesthetics but may be more generally reflective of the level of consciousness. The 40-Hz ASSR response in human EEG recordings was increased during ketamine anesthesia ([@CIT0030]), consistent with our finding of increased 40 Hz ASSR with MK-801 in rodents. Our studies differ, however, in that the humans were given a large enough dose of NMDAR antagonist to induce unconsciousness, whereas the rodents in our study were given a low dose and did not show any observable signs of altered consciousness. Given the sensitivity of the ASSR to level of alertness, we assert that in order for recordings in rodents to be a useful cross-species translational tool for SZ research, recordings must be done in the same state in both humans and rodents.

A strength of our approach in rodents is that we had the ability to record LFP and EEG signals simultaneously from multiple locations during the ASSR in unrestrained rats. This enabled us to probe the site of ASSR generation within the rodent brain. The most robust response we recorded was from within the A1 cortex, where we observed the highest magnitude of response and coherence, which is consistent with other animal studies suggesting that A1 cortex is a main generator of ASSR ([@CIT0008]; [@CIT0018]). We also analyzed the ASSR response with skull EEG electrodes, which were placed on the vertex, and LFP responses from the HP. Although coherence values in both sites were much lower than in the A1 cortex, we did observe a similar (albeit weaker) effect of MK-801 on 20-Hz ITC from skull EEG and 40-Hz ITC from HP field recordings. Given that LFPs and EEGs are known to be a summation of activity from a large area, we would expect the strong A1 cortex signals to spread via volume conduction and thus be evident in other nearby brain regions. Thus, the low EEG coherence we observed is likely due to signal spread and contamination from signals generated in other brain regions. To fully understand the whole brain dynamic and contributions to vertex EEG ITC, denser, well-distributed depth electrode recording is needed.

Much evidence suggests that GABAergic inhibition is responsible for oscillations and maintenance of synchronous firing ([@CIT0020]; [@CIT0009]; [@CIT0033]), which led us to also examine ASSR under acute GABA-A antagonism. Surprisingly, we did not observe any effect of PTX on ASSR generation at any of the frequencies tested. A previous study assessing ASSR in rats with the GABA-A agonist muscimol found an increase in phase locking during 40 Hz ASSR ([@CIT0039]). We therefore hypothesized that blocking GABA-A channels would alter ITC at 40 Hz, but we did not observe this effect. While it is possible that dose was a factor, a slightly higher dose of PTX (1.0mg/kg) resulted in seizures in 3 of 4 rats tested. Therefore, the 0.5-mg/kg PTX dose was likely close to a maximal dose without epileptogenic activity. Using this same dose in another study, our group did find a significant reduction in beta-band oscillations from skull-EEG, suggesting that this dose is sufficient to alter neural oscillations. Overall, this study suggests that A1 coherence may be more sensitive to NMDAR-antagonism, which is thought to preferentially inhibit fast-spiking interneurons, than by direct GABA-A blockade, which would inhibit all GABA neurons. Further studies will be needed to fully parse out the role of GABA-A receptors in ASSR.

We have shown that acute MK-801 enhances ITC at 20 and 40 Hz, which is not consistent with the majority of ASSR EEG findings in SZ patients that have shown decreased 40-Hz ITC ([@CIT0019]; [@CIT0021]). However, this effect is highly consistent with a large body of animal literature demonstrating that NMDAR antagonists increased gamma frequency activities during resting conditions ([@CIT0028]; [@CIT0010]). In this study, 0.1mg/kg MK-801 was chosen to keep consistent with many previous studies showing electrophysiological and behavioral effects; however, there is evidence that the effects of NMDAR-antagonists vary strongly across doses ([@CIT0031]). It will be important for future studies to examine how ASSR is affected at multiple concentrations of MK-801. Interestingly, in this study, we did not find an increase in gamma power from the A1 cortex. This is consistent with our previous findings (Sullivan et al., 2014), where we found a significant increase in gamma power from the HP and skull-surface EEG sites, but not the A1 cortex. This indicates that the gamma-power--inducing effects may differ across brain regions. However, the fact that MK-801 did show increased ITC without change in power at A1 suggests that neuronal synchronization could be a more salient approach to detect acute MK-801 effects than power in this anatomic location. There is also evidence suggesting that elevated 40-Hz activity in the A1 cortex is correlated with positive symptoms, most specifically hallucinations ([@CIT0035]). Our data suggest that ASSR under MK-801 challenge may not reproduce the overall neural oscillation profile observed in SZ patients, although it may still mimic specific clinical components in SZ. More importantly, it may provide a useful translational paradigm for interrogating NMDAR mechanisms across animals and humans.
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